Tebotelimab clinical trials
Also written MGD013.
How each study uses tebotelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses tebotelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedPhase 2/3MacroGenicsNCT04082364Written as Tebotelimab
- MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsTerminatedPhase 1/2Zai Lab (Shanghai) Co., Ltd.NCT04212221Written as MGD013 monotherapy
- A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With MelanomaTerminatedPhase 1Zai Lab (Shanghai) Co., Ltd.NCT04653038Written as MGD013
- A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsCompletedPhase 1MacroGenicsNCT03219268Written as tebotelimab 1 mg
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedPhase 2MacroGenicsNCT04634825Written as Tebotelimab
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedPhase 1Zai Lab (Shanghai) Co., Ltd.NCT04178460Written as Niraparib combined with MGD013
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnPhase 2/3MacroGenicsNCT04129320Written as MGD013
Codes
What other systems call tebotelimab · ClinicalTrials.gg INT017142
- UNII (FDA) L62556GPXBTEBOTELIMABOne source FDA
- NCI Thesaurus C143957TebotelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L62556GPXB | TEBOTELIMAB | One source FDA |
| NCI Thesaurus | C143957 | Tebotelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.